JP6464389B2 - Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud - Google Patents
Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud Download PDFInfo
- Publication number
- JP6464389B2 JP6464389B2 JP2014238962A JP2014238962A JP6464389B2 JP 6464389 B2 JP6464389 B2 JP 6464389B2 JP 2014238962 A JP2014238962 A JP 2014238962A JP 2014238962 A JP2014238962 A JP 2014238962A JP 6464389 B2 JP6464389 B2 JP 6464389B2
- Authority
- JP
- Japan
- Prior art keywords
- hypertension
- blood pressure
- therapeutic agent
- willow
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010020772 Hypertension Diseases 0.000 title claims description 56
- 239000003814 drug Substances 0.000 title claims description 24
- 229940124597 therapeutic agent Drugs 0.000 title claims description 21
- 235000013376 functional food Nutrition 0.000 title claims description 9
- 241000124033 Salix Species 0.000 title description 22
- 230000003449 preventive effect Effects 0.000 title description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 11
- 240000000275 Persicaria hydropiper Species 0.000 claims description 8
- 235000017337 Persicaria hydropiper Nutrition 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000035487 diastolic blood pressure Effects 0.000 description 17
- 230000035488 systolic blood pressure Effects 0.000 description 16
- 230000036772 blood pressure Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 235000013305 food Nutrition 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 7
- 230000001631 hypertensive effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000646858 Salix arbusculoides Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- -1 aliphatic alcohols Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Description
本発明は、高血圧症（特に塩分過剰摂取に起因する高血圧症）に有用な高血圧症の予防治療剤に関する。 The present invention relates to a prophylactic and therapeutic agent for hypertension useful for hypertension (particularly hypertension resulting from excessive intake of salt).
高血圧症は日本人において比較的多い高い病態であり、高血圧症由来の心臓病、脳卒中、動脈硬化等にみられるように、高血圧症はしばしば重大な症状を引き起こす危険因子である。高血圧症の主な原因は、喫煙、飲酒、運動不足、ストレスの蓄積、塩分の過剰摂取といった、食生活や日頃の生活習慣が関係することが多い。特に伝統的な日本食は、塩分が過剰であることが多いため、高齢化に伴い、高血圧症の患者は今後も増加すると予測されている。 Hypertension is a relatively high disease state in Japanese people, and hypertension is often a risk factor that causes serious symptoms, as seen in heart disease, stroke, arteriosclerosis, etc. derived from hypertension. The main causes of hypertension are often related to eating habits and daily lifestyle such as smoking, drinking, lack of exercise, accumulation of stress, and excessive intake of salt. In particular, traditional Japanese food is often excessive in salt, so it is predicted that the number of patients with hypertension will continue to increase as the population ages.
血圧は正常血圧に近づくほど、心臓病、脳卒中等の発症リスクが低減するため、高血圧症の予防及び治療が重要であり、食事療法、運動療法、薬物療法等が実施されている。
高血圧症の薬物療法は、食事療法や運動療法で血圧が正常化しない、症状が重い高血圧に対して行われ、確実な降圧が期待できる薬物が多用されている。このような薬物としては例えば、カルシウム拮抗薬、アンジオテンシンＩ変換酵素（ＡＣＥ）阻害薬、アンジオテンシンII受容体拮抗薬、利尿薬、交感神経抑制薬等が挙げられる（例えば、非特許文献１参照）。
As blood pressure approaches normal blood pressure, the risk of developing heart disease, stroke, and the like decreases, so prevention and treatment of hypertension is important, and diet therapy, exercise therapy, drug therapy, and the like are performed.
Drug therapy for hypertension is performed for hypertension with severe symptoms and blood pressure does not normalize with dietary therapy or exercise therapy, and drugs that can be expected to reliably reduce blood pressure are frequently used. Examples of such drugs include calcium antagonists, angiotensin I converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, diuretics, and sympathetic nerve inhibitors (see, for example, Non-Patent Document 1).
しかしながら、従来の血圧降下剤として用いられる薬物には、副作用を伴うものもあり、予防目的で長期間服用することについての安全性が確立されているとは必ずしも言えないのが実情である。そのため、経口投与で有効であり、天然物由来の高血圧症の予防治療剤の開発が望まれていた。
かかる状況下、本発明は、日常的に経口摂取しやすい、天然物由来の高血圧症の予防治療剤を提供することにある。
However, some of the drugs used as conventional antihypertensive agents have side effects, and it is not always possible to say that safety has been established for long-term use for preventive purposes. Therefore, it has been desired to develop a prophylactic / therapeutic agent for hypertension derived from natural products that is effective for oral administration.
Under such circumstances, it is an object of the present invention to provide a prophylactic / therapeutic agent for hypertension derived from natural products, which is easily taken orally on a daily basis.
本発明者は、上記課題を解決すべく鋭意研究を重ねた結果、ヤナギタデに含有される成分が、高血圧症の予防・改善に有用であることを見出し、本発明に至った。 As a result of intensive studies to solve the above-mentioned problems, the present inventor has found that the component contained in Yanagita is useful for the prevention and improvement of hypertension, leading to the present invention.
＜１＞ ヤナギタデ（Persicaria hydropiper）の芽の乾燥物を有効成分として含有する塩分過剰摂取に起因する高血圧症の予防及び/又は治療のため、並びに心拍数増加の抑制のための高血圧症の予防治療剤
＜２＞ 前記＜１＞に記載の高血圧症の予防治療剤を配合した機能性食品。
＜３＞ ヤナギタデ（Persicaria hydropiper）の芽の乾燥粉砕物。
<1> Preventive treatment of hypertension for the prevention and / or treatment of hypertension caused by excessive intake of salt containing the dried bud of Persicaria hydropiper as an active ingredient, and for suppression of heart rate increase <2> A functional food containing the prophylactic and therapeutic agent for hypertension according to <1>.
<3> A dried pulverized product of Persicaria hydropiper buds.
本発明によれば、高血圧症の予防や治療に有用で、経口摂取可能な天然物由来の高血圧症の予防治療剤が提供される。該予防治療剤を含有する機能性食品は、安全で嗜好的にも優れ、日常的に経口摂取しやすく、高血圧症の予防や治療の予防・改善目的に長期間服用することができる。 According to the present invention, a prophylactic / therapeutic agent for hypertension derived from natural products that is useful for the prevention and treatment of hypertension and can be taken orally is provided. The functional food containing the prophylactic and therapeutic agent is safe and excellent in taste, easy to be taken orally on a daily basis, and can be taken for a long time for the purpose of preventing hypertension and preventing or improving treatment.
以下、本発明について例示物等を示して詳細に説明するが、本発明は以下の例示物等に限定されるものではなく、本発明の要旨を逸脱しない範囲において任意に変更して実施できる。 Hereinafter, the present invention will be described in detail with reference to examples and the like, but the present invention is not limited to the following examples and the like, and can be arbitrarily modified and implemented without departing from the gist of the present invention.
本発明は、イヌタデ属植物の乾燥物及び／又は抽出物を有効成分として含有する高血圧症の予防治療剤（以下、「本発明の予防治療剤」と称する場合がある。）に関する。なお、「高血圧症の予防治療剤」とは、高血圧症の予防や改善作用を有するものを意味する。すなわち、高血圧症の発症者に対しては血圧降下作用により正常に近い血圧に戻し、健常者の血圧を降下させるものではない。 The present invention relates to a prophylactic / therapeutic agent for hypertension (hereinafter sometimes referred to as “the prophylactic / therapeutic agent of the present invention”) containing a dried product and / or an extract of the genus Inodade as an active ingredient. Note that “a prophylactic / therapeutic agent for hypertension” means an agent having an effect of preventing or improving hypertension. That is, it does not lower the blood pressure of a healthy person by returning the blood pressure to a normal blood pressure by a blood pressure lowering action for those who develop hypertension.
本発明の予防治療剤の対象となる高血圧症は特に制限されるものではなく、塩分の過剰摂取、運動不足、喫煙、飲酒、ストレスの蓄積等に起因する高血圧症に対して有効である。塩分過剰摂取に起因する高血圧症は、本発明の予防治療剤が特に有効な高血圧症の一つである。 Hypertension which is a target of the preventive and therapeutic agent of the present invention is not particularly limited, and is effective for hypertension caused by excessive intake of salt, lack of exercise, smoking, drinking, accumulation of stress, and the like. Hypertension due to excessive intake of salt is one of the hypertensions for which the preventive and therapeutic agent of the present invention is particularly effective.
本発明の高血圧症の予防治療剤の原材料となるイヌタデ属植物としては、ヤナギタデ（Persicaria hydropiper）が挙げられる。
また、ヤナギタデは、芽はさしみのつま、タデ酢等として食用にされており、経口投与しても安全である。
An example of the plant belonging to the genus Inodade, which is a raw material for the prophylactic and therapeutic agent for hypertension of the present invention, is Persicaria hydropiper.
Yanagita is edible as sprout, vinegar, and so on, and it is safe to administer orally.
原料植物における使用できる部位としては、例えば、地上部、根部、実等が挙げられる。原料植物は、形状や種類は限定されることなく任意のものを使用でき、事前処理せずにそのまま使用することができるうえ、スライス、粉砕、圧搾またはすりおろす等により、細粒物として使用することもできる。 As a site | part which can be used in a raw material plant, a ground part, a root part, a fruit, etc. are mentioned, for example. The raw material plant can be used in any form without limitation in shape and type, and can be used as it is without pretreatment, and it can be used as a fine-grained product by slicing, crushing, pressing or grated, etc. You can also.
本発明において、「乾燥物」とは原料植物を乾燥したものである。具体的にはヤナギタデを、天日乾燥、加熱乾燥、フリーズドライ等の公知の乾燥方法で乾燥したものである。
乾燥物は、使用性の観点から、通常、粉砕して粉末化され、乾燥粉砕物として使用される。粉砕方法は、特に限定はなく従来公知の粉砕器を使用すればよい。粉末の粒径は、その使用態様によって適宜決定される。
In the present invention, the “dried product” is a dried material plant. Specifically, the willow tree is dried by a known drying method such as sun drying, heat drying, freeze drying or the like.
From the viewpoint of usability, the dried product is usually pulverized into powder and used as a dried pulverized product. The pulverization method is not particularly limited, and a conventionally known pulverizer may be used. The particle size of the powder is appropriately determined depending on the use mode.
本発明において、「抽出物」とは、対象となる原料植物、又はこれを必要に応じて乾燥、細切したものを、圧搾又は溶媒抽出するなどして、有効成分の含有量を高めた形態のものを総括した概念である。具体的にはヤナギタデを抽出原料として得られる抽出液、該抽出液の希釈液若しくは濃縮液、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。なお、抽出液を乾燥して得られる乾燥物も、抽出物に該当するものとする。 In the present invention, the “extract” is a form in which the content of the active ingredient is increased by pressing or solvent extracting a target raw plant, or a dried, shredded product as necessary. It is a concept that summarizes things. Specifically, an extract obtained by using Yanagita as an extraction raw material, a diluted solution or a concentrated solution of the extract, or a crudely purified product or a purified product thereof are included. In addition, the dried material obtained by drying an extract liquid shall also correspond to an extract.
抽出処理に使用する抽出溶媒の具体例としては、水、メタノール、エタノール、プロパノール等の低級脂肪族アルコールが挙げられる。これらの抽出溶媒は単独又はこれら２種以上の混合物として使用することができ、２種以上の溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。 Specific examples of the extraction solvent used for the extraction treatment include lower aliphatic alcohols such as water, methanol, ethanol, and propanol. These extraction solvents can be used alone or as a mixture of two or more thereof. When a mixture of two or more solvents is used as the extraction solvent, the mixing ratio can be appropriately adjusted.
なお、抽出溶媒には、本発明の効果を損なわない範囲で添加剤を含んでいてもよい。例えば、ｐＨ調整剤、粘度調整剤などが挙げられる。 The extraction solvent may contain an additive as long as the effects of the present invention are not impaired. For example, a pH adjuster, a viscosity adjuster, etc. are mentioned.
原料植物から抽出物を抽出する方法は特に限定されず、常法に従って行なれる。例えば、原料植物を抽出溶媒に浸漬し、室温あるいは加熱して原料植物に含まれる可溶性成分を抽出する方法が挙げられる。また、抽出物に含まれる残渣を取り除くため、濾過や遠心分離を行ってもよい。また、得られた抽出液はそのまま利用してもよいが、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。 The method for extracting the extract from the raw material plant is not particularly limited, and can be performed according to a conventional method. For example, the raw material plant is immersed in an extraction solvent, and the method of extracting the soluble component contained in a raw material plant by heating at room temperature or is mentioned. Moreover, in order to remove the residue contained in the extract, filtration or centrifugation may be performed. Moreover, although the obtained extract may be used as it is, it may be subjected to treatments such as dilution, concentration, drying and purification according to a conventional method.
以上のようにして得られるヤナギタデの乾燥物及び／又は抽出物は、高血圧症の発症者に対して血圧降下作用を有する。そのため、当該乾燥物及び／又は抽出物を高血圧症の予防治療剤の有効成分として利用することができる。
上記ヤナギタデの乾燥物及び抽出物は、それぞれ単独で使用してもよいし、混合して使用してもよい。製造が容易である点では乾燥物が好ましい。
The dry willow and / or extract of the willow tree obtained as described above has a blood pressure lowering effect on a hypertensive person. Therefore, the dried product and / or the extract can be used as an active ingredient of a prophylactic / therapeutic agent for hypertension.
The dry and extract of the above willow may be used alone or in combination. A dry product is preferable in terms of easy production.
本発明の高血圧症の予防治療剤の形態は、特に制限されず使用する用途により適宜選択することができる。具体的には粉末状、顆粒状、カプセル状、タブレット状、グミ状、ガム状、キャンディー状、丸剤、錠剤状、棒状、板状、液状、クリーム状、軟膏状、シート状等の剤型・形態をとることができる。この中でも、顆粒状、カプセル状、タブレット状、液状であることが好ましい。
なお、製剤化する場合、保存や取扱いを容易にするために、薬学的に許容され得るキャリア（デキストリン等）やその他任意の助剤を添加することができる。
The form of the prophylactic / therapeutic agent for hypertension of the present invention is not particularly limited and can be appropriately selected depending on the intended use. Specifically, dosage forms such as powder, granules, capsules, tablets, gummi, gums, candy, pills, tablets, rods, plates, liquids, creams, ointments, sheets, etc.・ It can take a form. Among these, granular, capsule, tablet, and liquid are preferable.
In addition, when formulating, in order to facilitate storage and handling, a pharmaceutically acceptable carrier (dextrin etc.) and other optional auxiliaries can be added.
本発明の高血圧症の予防治療剤の摂取量は、対象者の年齢、性別などの個別差にもよって変化すると考えられるが、１日当たり、５０ｍｇ〜５００ｍｇ程度である。摂取量が少な過ぎると血圧降下作用が十分発揮しないのはもちろんであるが、摂取量が多過ぎても血圧降下作用のそれ以上の改善はみられない。 The intake of the prophylactic and therapeutic agent for hypertension of the present invention is considered to vary depending on individual differences such as the age and sex of the subject, but is about 50 mg to 500 mg per day. Of course, if the intake is too small, the blood pressure lowering effect is not sufficiently exhibited.
本発明の高血圧症の予防治療剤は、天然物由来であるため、安全で嗜好的にも優れる。そのため、日常的に経口摂取しやいように、各種の食品、飲料と混ぜて機能性食品とすることで、長期的に摂取することも容易である。
ここでいう「機能性食品」とは、一般食品に加えて、健康食品、栄養補助食品、栄養機能食品、栄養保険食品等、健康の維持の目的で摂取する食品および／又は飲料を意味している。なお、機能性食品として製品化する場合には、食品に用いられる様々な添加剤、具体的には、着色料、保存料、増粘安定剤、酸化防止剤漂白剤、防菌防黴剤、酸味料、調味料、乳化剤、強化剤、製造用剤、香料等を添加していてもよい。
Since the prophylactic and therapeutic agent for hypertension of the present invention is derived from natural products, it is safe and excellent in taste. Therefore, it is easy to take for a long time by mixing with various foods and beverages to make a functional food so that it can be taken orally on a daily basis.
The term “functional food” as used herein means foods and / or beverages ingested for the purpose of maintaining health, such as health foods, nutritional supplements, functional nutritional foods, nutrition insurance foods, in addition to general foods. Yes. In addition, when commercializing as a functional food, various additives used in food, specifically, coloring agents, preservatives, thickening stabilizers, antioxidant bleaching agents, antibacterial and antifungal agents, A sour agent, a seasoning, an emulsifier, a reinforcing agent, a manufacturing agent, a fragrance and the like may be added.
本発明の機能性食品の対象となる、食品、飲料は特に限定されるものではない。例えば、食品として、ソーセージ、ハム、魚介加工品、ゼリー、キャンディー、チューインガムなどの食品類が挙げられる。また、飲料としては、各種の茶類、清涼飲料水、酒類、栄養ドリンクなどが挙げられる。
本発明の高血圧症の予防治療剤は、このような食品、飲料に添加することにより、簡易に経口摂取することができる。
The foods and beverages that are the targets of the functional food of the present invention are not particularly limited. Examples of food include foods such as sausage, ham, processed seafood, jelly, candy, and chewing gum. Examples of the beverage include various teas, soft drinks, alcoholic beverages, and energy drinks.
The prophylactic / therapeutic agent for hypertension of the present invention can be easily taken orally by adding to such foods and beverages.
本発明の高血圧症の予防治療剤は、ヒト以外の動物に対して適用することもできる。そのため、動物用の高血圧症の予防治療剤として使用してもよく、また、ペットフード等の動物用機能性食品へ添加することもできる。 The prophylactic / therapeutic agent for hypertension of the present invention can also be applied to animals other than humans. Therefore, it may be used as an agent for preventing and treating hypertension for animals, and can also be added to functional foods for animals such as pet foods.
以下、実施例により本発明を更に詳細に説明するが、本発明は、その要旨を変更しない限り以下の実施例に限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to a following example, unless the summary is changed.
「実験例１」
（原料植物）
ヤナギタデ（「ＪＡ筑前あさくら」の紅たで部会から購入）の芽の部分を、フリーズドライヤーFD-80（東京理化器械（株）製）で乾燥し、ヤナギタデ乾燥物を得た。得られたヤナギタデ乾燥物を、ミクロパウダー（ウェスト社製）で十分に粉砕し、ヤナギタデ乾燥粉砕物とした。
"Experiment 1"
(Raw plant)
The sprout part of Yanagitade (purchased from “Red Chide Asakura” of JA Chikuzen Asakura) was dried with freeze dryer FD-80 (manufactured by Tokyo Rika Kikai Co., Ltd.) to obtain a dried Yanagitade. The obtained dried willow pulverized product was sufficiently pulverized with micropowder (manufactured by West Co., Ltd.) to obtain a dried willow pulverized product.
（実験動物）
実験動物は、日本SLCより入手した野生型マウス(C57BL/6J)を用いた。飼育は温度２４±１℃、湿度５０-６０％、照明は１２時間明暗サイクルで調節された実験動物飼育室にて行った。
なお、特に断りのない限り飼料としてＣＥ-２（日本クレハ）を、飲料水として２重量％の食塩水を用い、自由摂食させた。
(Experimental animals)
The experimental animal used was a wild type mouse (C57BL / 6J) obtained from Japan SLC. The animals were raised in a laboratory animal room where the temperature was 24 ± 1 ° C., the humidity was 50-60%, and the lighting was controlled by a 12-hour light / dark cycle.
Unless otherwise specified, CE-2 (Nippon Kureha) was used as feed and 2% by weight saline was used as drinking water, and was allowed to eat freely.
（収縮期血圧及び拡張期血圧の測定）
１群５匹のマウスに、上記飼料及び食塩水と共に、上述のヤナギタデ乾燥粉砕物を２５０ｍｇ/ｋｇ/ｄａｙで与え、試験群（実施例）とした。また、１群５匹のマウスに、上記飼料及び食塩水のみを与え、コントロール群（比較例）とした。
試験群、コントロール群のマウスの収縮期血圧、拡張期血圧および心拍数について１２週間継続して測定した。なお、統計処理は二元配置の分散分析で行った。有意水準はＰ＜０．０５とした。
(Measurement of systolic blood pressure and diastolic blood pressure)
A group of 5 mice was given the above-mentioned dry crushed dried yagita at 250 mg / kg / day together with the above feed and saline, to give a test group (Example). Moreover, only the said feed and salt solution were given to 5 mice per group, and it was set as the control group (comparative example).
The systolic blood pressure, diastolic blood pressure, and heart rate of the test group and control group mice were measured continuously for 12 weeks. Statistical processing was performed by two-way analysis of variance. The significance level was P <0.05.
図１に収縮期血圧、図２に拡張期血圧の結果をそれぞれ示す。
２％食塩水を摂取した高食塩コントロール群のマウスでは、４週目頃から収縮期血圧および拡張期血圧の上昇が認められた。後述の参考例に示すように、コントロール群のマウスは中等度高血圧症を発症したと認められる。
一方、２％食塩水及びヤナギタデ乾燥粉砕物を摂取した試験群のマウスでは、４週目頃からの収縮期血圧および拡張期血圧の上昇が対照群に比して有意に抑制された。
このように試験群及びコントロール群のマウスを比較すると、試験群で４週目からの降圧作用が統計的に有意であった。この結果からヤナギタデ乾燥粉砕物には高血圧症の予防治療作用があることが示された。また、試験群及びコントロール群のマウスの１２週目の心拍数は、それぞれ７６５±３拍/分、８０１±９拍/分であり、有意差を認め、ヤナギタデ乾燥物の投与で抑制されていた。
なお、試験群、コントロール群それぞれのマウスにおいて、経時的体重、飲水、摂餌および尿量について両群間に統計的有意差は認められなかった。このことから、ヤナギタデ乾燥粉砕物には急性毒性および亜急性毒性が無いことと観察されている降圧効果はヤナギタデ乾燥粉砕物による直接効果であることが示唆される。
FIG. 1 shows the results of systolic blood pressure, and FIG. 2 shows the results of diastolic blood pressure.
Increased systolic blood pressure and diastolic blood pressure were observed from around the 4th week in the high saline control group mice ingesting 2% saline. As shown in the reference examples described later, it is recognized that the mice in the control group developed moderate hypertension.
On the other hand, in the mice of the test group that ingested 2% saline and dry ground willow, the increase in systolic blood pressure and diastolic blood pressure from around the 4th week was significantly suppressed as compared to the control group.
Thus, when the mice of the test group and the control group were compared, the antihypertensive effect from the 4th week was statistically significant in the test group. From these results, it was shown that the dried ground willow has an effect of preventing and treating hypertension. Moreover, the heart rate of the 12th week of the mouse | mouth of a test group and a control group was 765 +/- 3 beat / min and 801 +/- 9 beat / min, respectively, and the significant difference was recognized and it was suppressed by administration of a dried willow tree. .
In each mouse of the test group and the control group, no statistically significant difference was observed between the two groups regarding body weight, drinking water, food intake, and urine volume over time. This suggests that the antihypertensive effect observed to be free of acute and subacute toxicities in dry ground millet is a direct effect of dry ground millet.
「参考例」
上記「実験例１」と同様のマウスを用い、飲料水として２重量％の食塩水を与えた群、（食塩を含まない）水を与えた群、収縮期血圧の変化を評価した結果を図３に示す。
２重量％の食塩水を与えた群では血圧が上昇しており、高血圧症を発症していると認められる。
Reference example
FIG. 4 shows the results of evaluating changes in systolic blood pressure using the same mouse as in “Experimental Example 1”, a group given 2% by weight saline as drinking water, a group given water (without salt), and water. 3 shows.
In the group given 2% by weight of saline, the blood pressure was elevated, and it is recognized that hypertension has developed.
「実験例２」
（原料植物）
ヤナギタデ（「ＪＡ筑前あさくら」の紅たで部会から購入）の芽の部分を、熱風乾燥（約８０℃）で乾燥し、ヤナギタデ乾燥物を得た。得られたヤナギタデ乾燥物を、ミクロパウダー（ウェスト社製）で十分に粉砕し、ヤナギタデ乾燥粉砕物とした。
"Experimental example 2"
(Raw plant)
The sprout part of Yanagitade (purchased from “Red Chieda Sakura” of “JA Chikuzen Asakura”) was dried by hot air drying (about 80 ° C.) to obtain a dried Yanagitade product. The obtained dried willow pulverized product was sufficiently pulverized with micropowder (manufactured by West Co., Ltd.) to obtain a dried willow pulverized product.
以下の５群（コントロール群、試験群１〜４）で、心拍数(Heart Rate)、収縮期血圧(Systolic Blood Pressure、ＳＢＰ)、拡張期血圧(Diastolic Blood Pressure、ＤＢＰ)、平均血圧（Mean Blood Pressure、ＭＢＰ）の評価を行った。
実験動物として、日本SLCより入手した野生型マウス(C57BL/6J)、温度２４±１℃、湿度５０-６０％、照明は１２時間明暗サイクルで調節された実験動物飼育室にて飼育した。飼料としてＣＥ-２（日本クレハ）を、飲料水として２重量％の食塩水を用い、自由摂食させた。
例数は各群Ｎ＝６で実験を開始し、実験途中で死亡するマウスは認められなかった。また、各群において、体重、摂餌量および摂水量に差異は認められなかった。
In the following 5 groups (control group, test groups 1 to 4), heart rate (Heart Rate), systolic blood pressure (SBP), diastolic blood pressure (Diastolic Blood Pressure, DBP), mean blood pressure (Mean Blood) Pressure, MBP) was evaluated.
As an experimental animal, a wild-type mouse (C57BL / 6J) obtained from Japan SLC was reared in a laboratory animal breeding room in which the temperature was 24 ± 1 ° C., the humidity was 50-60%, and the lighting was controlled by a 12-hour light / dark cycle. CE-2 (Nippon Kureha) was used as the feed, and 2% by weight saline was used as the drinking water.
As for the number of cases, the experiment was started with N = 6 for each group, and no mouse died during the experiment. In each group, there was no difference in body weight, food intake and water intake.
＜コントロール群（食塩水のみ）＞
６匹のマウスに、飼料としてＣＥ-２（日本クレハ）を自由摂食させ、飲料水として２重量％の食塩水を用いて、３か月間２％の食塩水溶液を負荷した食塩依存性高血圧マウスを作製した。食塩依存性高血圧マウスに対し、さらにその後、同条件で飼育を行い、８週間各週ごとに上記評価を行った。
<Control group (saline solution only)>
Salt-dependent hypertensive mice in which 6 mice were freely fed CE-2 (Kureha, Japan) as feed, 2% saline was used as drinking water, and 2% saline solution was loaded for 3 months Was made. Thereafter, the salt-dependent hypertensive mice were reared under the same conditions, and the evaluation was performed every week for 8 weeks.
＜試験群１（ヤナギタデ乾燥物投与：５００ｍｇ/ｋｇ/ｄａｙ）＞
コントロール群と同様に作製した食塩依存性高血圧マウス（６匹）に対し、上記飼料及び食塩水と共に、ヤナギタデ乾燥粉砕物を５００ｍｇ/ｋｇ/ｄａｙで与え、８週間各週ごとに上記評価を行った。
<Test Group 1 (Dried Yanagidae: 500 mg / kg / day)>
Salt-dependent hypertensive mice (six mice) prepared in the same manner as in the control group were given a dry ground willow with 500 mg / kg / day together with the above feed and saline, and the above evaluation was performed every week for 8 weeks.
＜試験群２（ヤナギタデ乾燥物投与：２５０ｍｇ/ｋｇ/ｄａｙ）＞
コントロール群と同様に作製した食塩依存性高血圧マウス（６匹）に対し、上記飼料及び食塩水と共に、ヤナギタデ乾燥粉砕物を２５０ｍｇ/ｋｇ/ｄａｙで与え、８週間各週ごとに上記評価を行った。
<Test Group 2 (Dried Yanagidae Administration: 250 mg / kg / day)>
Salt-dependent hypertensive mice (6 mice) produced in the same manner as in the control group were given a dry ground willow with 250 mg / kg / day together with the above-mentioned feed and saline, and the above-mentioned evaluation was performed every week for 8 weeks.
＜試験群３（ヤナギタデ乾燥物投与：１２５ｍｇ/ｋｇ/ｄａｙ）＞
コントロール群と同様に作製した食塩依存性高血圧マウス（６匹）に対し、上記飼料及び食塩水と共に、ヤナギタデ乾燥粉砕物を１２５ｍｇ/ｋｇ/ｄａｙで与え、８週間各週ごとに上記評価を行った。
<Test group 3 (administered dry willow: 125 mg / kg / day)>
Salt-dependent hypertensive mice (6 mice) prepared in the same manner as in the control group were given a dry ground willow with 125 mg / kg / day together with the above feed and saline, and the above evaluation was performed every week for 8 weeks.
＜試験群４（ヤナギタデ乾燥物投与：６２．５ｍｇ/ｋｇ/ｄａｙ）＞
コントロール群と同様に作製した食塩依存性高血圧マウス（６匹）に対し、上記飼料及び食塩水と共に、ヤナギタデ乾燥粉砕物を６２．５ｍｇ/ｋｇ/ｄａｙで与え、８週間各週ごとに上記評価を行った。
<Test Group 4 (Dried Yanagidae: 62.5 mg / kg / day)>
Salt-dependent hypertensive mice (six mice) prepared in the same manner as in the control group were given 62.5 mg / kg / day of the dry ground willow with the above feed and saline, and the above evaluation was performed every week for 8 weeks. It was.
コントロール群及び試験群１〜４の心拍数、収縮期血圧(ＳＢＰ)、拡張期血圧(ＤＢＰ)、平均血圧（ＭＢＰ）の評価結果を図４〜７に示す。なお、二元配置の分散分析を行い、事後検定にはボンフェローニを行った。有意水準はＰ＜０．０５とした。 Evaluation results of heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP) in the control group and test groups 1 to 4 are shown in FIGS. A two-way analysis of variance was performed, and Bonferroni was used for the post-test. The significance level was P <0.05.
図４〜７に示すように、コントロール群では食塩水投与３か月間、時間の経過とともに、心拍数の増加と、収縮期血圧、拡張期血圧および平均血圧の上昇が認められ、その状態が試験期間持続していた。
一方、食塩水投与３か月間後に、ヤナギタデ乾燥物を投与した試験群１〜３では、コントロール群に比べてヤナギタデ乾燥物投与１週目から、心拍数の増加、収縮期血圧、拡張期血圧および平均血圧の上昇がいずれも抑制され始め、２週目以降では有意にそれぞれを抑制した。試験群４では収縮期血圧には影響しなかったが、平均血圧の上昇は投与７週目から、拡張期血圧の上昇は４週目からいずれも有意に抑制した。心拍数の増加には影響しなかった。
As shown in FIGS. 4-7, in the control group, increase in heart rate and increase in systolic blood pressure, diastolic blood pressure and average blood pressure were observed with the passage of time for 3 months in saline administration, and the state was tested. It lasted for a period.
On the other hand, in the test groups 1 to 3 administered with Yanagita dehydrated three months after the administration of saline, heart rate increased, systolic blood pressure, diastolic blood pressure and Each increase in average blood pressure began to be suppressed, and each was significantly suppressed after the second week. In test group 4, the systolic blood pressure was not affected, but the increase in mean blood pressure was significantly suppressed from the seventh week of administration, and the increase in diastolic blood pressure was significantly suppressed from the fourth week. It did not affect heart rate increase.
本発明の高血圧症の予防治療剤は、高血圧症の予防や治療に有用であり、天然物由来であるため経口摂取しても安全性が高い。そのため、日常的に経口摂取することで、高血圧症を予防し、改善することができる。 The prophylactic and therapeutic agent for hypertension of the present invention is useful for the prevention and treatment of hypertension, and since it is derived from natural products, it is highly safe even when taken orally. Therefore, daily oral intake can prevent and ameliorate hypertension.
Claims (2)
、 A functional food for the prevention and / or treatment of hypertension caused by excessive intake of salt containing the prophylactic / therapeutic agent for hypertension according to claim 1 and for suppressing an increase in heart rate .
,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014238962A JP6464389B2 (en) | 2012-11-29 | 2014-11-26 | Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012260932 | 2012-11-29 | ||
| JP2012260932 | 2012-11-29 | ||
| JP2014238962A JP6464389B2 (en) | 2012-11-29 | 2014-11-26 | Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013245121A Division JP2014129344A (en) | 2012-11-29 | 2013-11-27 | Prevention/therapeutic agent for hypertension, and functional food comprising the prevention/therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015042681A JP2015042681A (en) | 2015-03-05 |
| JP6464389B2 true JP6464389B2 (en) | 2019-02-06 |
Family
ID=51408100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013245121A Pending JP2014129344A (en) | 2012-11-29 | 2013-11-27 | Prevention/therapeutic agent for hypertension, and functional food comprising the prevention/therapeutic agent |
| JP2014238962A Active JP6464389B2 (en) | 2012-11-29 | 2014-11-26 | Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013245121A Pending JP2014129344A (en) | 2012-11-29 | 2013-11-27 | Prevention/therapeutic agent for hypertension, and functional food comprising the prevention/therapeutic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP2014129344A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016132483A1 (en) * | 2015-02-18 | 2016-08-25 | 学校法人福岡大学 | Human chymase inhibitor and drug for preventing and treating disease associated with human chymase activity |
| KR102336013B1 (en) * | 2019-11-29 | 2021-12-03 | 주식회사 코리아나화장품 | Cosmetic Composition For Improving Skin Elasticity Comprising Arrow-leaf Smartweed Extract As Active Ingredient |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0740881B2 (en) * | 1986-11-19 | 1995-05-10 | ダイセル化学工業株式会社 | Deodorant Key |
| JP3142411B2 (en) * | 1992-02-28 | 2001-03-07 | 丸善製薬株式会社 | Antioxidants and methods for producing antioxidants |
| JPH06135830A (en) * | 1992-10-23 | 1994-05-17 | Natl Sci Council | Antihypertensive medicine composition containing flavonoid derivative |
| JP4515556B2 (en) * | 1999-05-31 | 2010-08-04 | 日本製粉株式会社 | Fat accumulation inhibitor, anti-obesity agent, food additive, food and pet food |
| EP1208755B1 (en) * | 1999-07-02 | 2008-03-12 | Meiji Seika Kaisha Ltd. | Compositions for foods, process for producing the same and functional foods and drinks containing the same |
| JP4179981B2 (en) * | 2003-12-15 | 2008-11-12 | ライオン株式会社 | Thiol-S-methyltransferase inhibitor, halitosis generation inhibitor, and halitosis generation composition |
| JP5186628B2 (en) * | 2005-02-04 | 2013-04-17 | 株式会社 レオロジー機能食品研究所 | Method for preparing medicinal composition |
| JP2008255075A (en) * | 2007-04-09 | 2008-10-23 | Daidoo Dorinko Kk | Improving agent for vessel endothelium function and health food |
| JP5892436B2 (en) * | 2011-08-26 | 2016-03-23 | ビーエイチエヌ株式会社 | Antihypertensive |
-
2013
- 2013-11-27 JP JP2013245121A patent/JP2014129344A/en active Pending
-
2014
- 2014-11-26 JP JP2014238962A patent/JP6464389B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015042681A (en) | 2015-03-05 |
| JP2014129344A (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009167195A (en) | Agent against stress-induced disease | |
| CN107708688A (en) | Use native compound and/or the method for dietary therapy inflammation | |
| JP6345243B2 (en) | Enbu fermented food or beverage composition | |
| JP6464389B2 (en) | Preventive and therapeutic agent for hypertension, functional food containing the same, and dried product of willow bud | |
| ES2808626T3 (en) | Composition for the use of cinnamaldehyde and zinc to manage weight | |
| WO2014010658A1 (en) | Preparation containing indian long pepper | |
| KR101045279B1 (en) | Composition of functional food with weight loss effect | |
| JP5848428B2 (en) | Oral pharmaceutical composition and functional food | |
| JP2009196931A (en) | Antiobestic agent and food and drink using the same | |
| WO2012036208A1 (en) | Fat oxidation or energy metabolism enhancer | |
| JP7029141B2 (en) | Composition for improving peripheral neuropathy | |
| JP2013249260A (en) | Senescence retardant | |
| CN106349318B (en) | A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared | |
| KR101478196B1 (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of Cudrania tricuspidata as a main component | |
| CN116077474A (en) | Methods and compositions for increasing energy expenditure using cinnamaldehyde | |
| KR101221623B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of root of vitis | |
| WO2018101231A1 (en) | Composition for sympathetic nerve activation | |
| JP6698034B2 (en) | Oral composition for improving systemic symptoms such as chills | |
| KR102323577B1 (en) | Composition for preventing or treating depression comprising mixed extract of Dioscorea nipponica Makino and Prickly Pear | |
| EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
| JP5749469B2 (en) | Antihypertensive | |
| KR20130065117A (en) | Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity | |
| JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
| JP4974475B2 (en) | Composition for prevention and / or treatment of pruritus containing acacia bark-derived material | |
| KR20060085731A (en) | Composition for inhibiting alcohol absorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170106 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170718 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170914 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20171011 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20171013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180417 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180605 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180815 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181120 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181210 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6464389 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |